Global Urinary Antispasodics Market Research Report 2023

Publication ID:

PB501232592

Publication Date:

January 20, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Urinary Antispasodics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Urinary Antispasodics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Urinary Antispasodics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Urinary Antispasodics in Men is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Urinary Antispasodics include Pfizer, Piramal Pharma Solutions, Allergan, Astellas, Eywa Pharma, Rising Pharmaceuticals, Otto Brandes GmbH, Recordati and Antares Pharma, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Urinary Antispasodics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urinary Antispasodics.
The Urinary Antispasodics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Urinary Antispasodics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Urinary Antispasodics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Piramal Pharma Solutions
Allergan
Astellas
Eywa Pharma
Rising Pharmaceuticals
Otto Brandes GmbH
Recordati
Antares Pharma
Accord Healthcare
Heritage Pharmaceuticals
Lannett
Leading Pharma
Major Pharmaceuticals
Segment by Type
10 mg
20 mg
30 mg
Others
Segment by Application
Men
Women
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Urinary Antispasodics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Urinary Antispasodics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 10 mg
1.2.3 20 mg
1.2.4 30 mg
1.2.5 Others
1.3 Market by Application
1.3.1 Global Urinary Antispasodics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Men
1.3.3 Women
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Urinary Antispasodics Market Perspective (2018-2029)
2.2 Urinary Antispasodics Growth Trends by Region
2.2.1 Global Urinary Antispasodics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Urinary Antispasodics Historic Market Size by Region (2018-2023)
2.2.3 Urinary Antispasodics Forecasted Market Size by Region (2024-2029)
2.3 Urinary Antispasodics Market Dynamics
2.3.1 Urinary Antispasodics Industry Trends
2.3.2 Urinary Antispasodics Market Drivers
2.3.3 Urinary Antispasodics Market Challenges
2.3.4 Urinary Antispasodics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Urinary Antispasodics Players by Revenue
3.1.1 Global Top Urinary Antispasodics Players by Revenue (2018-2023)
3.1.2 Global Urinary Antispasodics Revenue Market Share by Players (2018-2023)
3.2 Global Urinary Antispasodics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Urinary Antispasodics Revenue
3.4 Global Urinary Antispasodics Market Concentration Ratio
3.4.1 Global Urinary Antispasodics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Urinary Antispasodics Revenue in 2022
3.5 Urinary Antispasodics Key Players Head office and Area Served
3.6 Key Players Urinary Antispasodics Product Solution and Service
3.7 Date of Enter into Urinary Antispasodics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Urinary Antispasodics Breakdown Data by Type
4.1 Global Urinary Antispasodics Historic Market Size by Type (2018-2023)
4.2 Global Urinary Antispasodics Forecasted Market Size by Type (2024-2029)
5 Urinary Antispasodics Breakdown Data by Application
5.1 Global Urinary Antispasodics Historic Market Size by Application (2018-2023)
5.2 Global Urinary Antispasodics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Urinary Antispasodics Market Size (2018-2029)
6.2 North America Urinary Antispasodics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Urinary Antispasodics Market Size by Country (2018-2023)
6.4 North America Urinary Antispasodics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Urinary Antispasodics Market Size (2018-2029)
7.2 Europe Urinary Antispasodics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Urinary Antispasodics Market Size by Country (2018-2023)
7.4 Europe Urinary Antispasodics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Urinary Antispasodics Market Size (2018-2029)
8.2 Asia-Pacific Urinary Antispasodics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Urinary Antispasodics Market Size by Region (2018-2023)
8.4 Asia-Pacific Urinary Antispasodics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Urinary Antispasodics Market Size (2018-2029)
9.2 Latin America Urinary Antispasodics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Urinary Antispasodics Market Size by Country (2018-2023)
9.4 Latin America Urinary Antispasodics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Urinary Antispasodics Market Size (2018-2029)
10.2 Middle East & Africa Urinary Antispasodics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Urinary Antispasodics Market Size by Country (2018-2023)
10.4 Middle East & Africa Urinary Antispasodics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Urinary Antispasodics Introduction
11.1.4 Pfizer Revenue in Urinary Antispasodics Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Piramal Pharma Solutions
11.2.1 Piramal Pharma Solutions Company Detail
11.2.2 Piramal Pharma Solutions Business Overview
11.2.3 Piramal Pharma Solutions Urinary Antispasodics Introduction
11.2.4 Piramal Pharma Solutions Revenue in Urinary Antispasodics Business (2018-2023)
11.2.5 Piramal Pharma Solutions Recent Development
11.3 Allergan
11.3.1 Allergan Company Detail
11.3.2 Allergan Business Overview
11.3.3 Allergan Urinary Antispasodics Introduction
11.3.4 Allergan Revenue in Urinary Antispasodics Business (2018-2023)
11.3.5 Allergan Recent Development
11.4 Astellas
11.4.1 Astellas Company Detail
11.4.2 Astellas Business Overview
11.4.3 Astellas Urinary Antispasodics Introduction
11.4.4 Astellas Revenue in Urinary Antispasodics Business (2018-2023)
11.4.5 Astellas Recent Development
11.5 Eywa Pharma
11.5.1 Eywa Pharma Company Detail
11.5.2 Eywa Pharma Business Overview
11.5.3 Eywa Pharma Urinary Antispasodics Introduction
11.5.4 Eywa Pharma Revenue in Urinary Antispasodics Business (2018-2023)
11.5.5 Eywa Pharma Recent Development
11.6 Rising Pharmaceuticals
11.6.1 Rising Pharmaceuticals Company Detail
11.6.2 Rising Pharmaceuticals Business Overview
11.6.3 Rising Pharmaceuticals Urinary Antispasodics Introduction
11.6.4 Rising Pharmaceuticals Revenue in Urinary Antispasodics Business (2018-2023)
11.6.5 Rising Pharmaceuticals Recent Development
11.7 Otto Brandes GmbH
11.7.1 Otto Brandes GmbH Company Detail
11.7.2 Otto Brandes GmbH Business Overview
11.7.3 Otto Brandes GmbH Urinary Antispasodics Introduction
11.7.4 Otto Brandes GmbH Revenue in Urinary Antispasodics Business (2018-2023)
11.7.5 Otto Brandes GmbH Recent Development
11.8 Recordati
11.8.1 Recordati Company Detail
11.8.2 Recordati Business Overview
11.8.3 Recordati Urinary Antispasodics Introduction
11.8.4 Recordati Revenue in Urinary Antispasodics Business (2018-2023)
11.8.5 Recordati Recent Development
11.9 Antares Pharma
11.9.1 Antares Pharma Company Detail
11.9.2 Antares Pharma Business Overview
11.9.3 Antares Pharma Urinary Antispasodics Introduction
11.9.4 Antares Pharma Revenue in Urinary Antispasodics Business (2018-2023)
11.9.5 Antares Pharma Recent Development
11.10 Accord Healthcare
11.10.1 Accord Healthcare Company Detail
11.10.2 Accord Healthcare Business Overview
11.10.3 Accord Healthcare Urinary Antispasodics Introduction
11.10.4 Accord Healthcare Revenue in Urinary Antispasodics Business (2018-2023)
11.10.5 Accord Healthcare Recent Development
11.11 Heritage Pharmaceuticals
11.11.1 Heritage Pharmaceuticals Company Detail
11.11.2 Heritage Pharmaceuticals Business Overview
11.11.3 Heritage Pharmaceuticals Urinary Antispasodics Introduction
11.11.4 Heritage Pharmaceuticals Revenue in Urinary Antispasodics Business (2018-2023)
11.11.5 Heritage Pharmaceuticals Recent Development
11.12 Lannett
11.12.1 Lannett Company Detail
11.12.2 Lannett Business Overview
11.12.3 Lannett Urinary Antispasodics Introduction
11.12.4 Lannett Revenue in Urinary Antispasodics Business (2018-2023)
11.12.5 Lannett Recent Development
11.13 Leading Pharma
11.13.1 Leading Pharma Company Detail
11.13.2 Leading Pharma Business Overview
11.13.3 Leading Pharma Urinary Antispasodics Introduction
11.13.4 Leading Pharma Revenue in Urinary Antispasodics Business (2018-2023)
11.13.5 Leading Pharma Recent Development
11.14 Major Pharmaceuticals
11.14.1 Major Pharmaceuticals Company Detail
11.14.2 Major Pharmaceuticals Business Overview
11.14.3 Major Pharmaceuticals Urinary Antispasodics Introduction
11.14.4 Major Pharmaceuticals Revenue in Urinary Antispasodics Business (2018-2023)
11.14.5 Major Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Piramal Pharma Solutions
Allergan
Astellas
Eywa Pharma
Rising Pharmaceuticals
Otto Brandes GmbH
Recordati
Antares Pharma
Accord Healthcare
Heritage Pharmaceuticals
Lannett
Leading Pharma
Major Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂